(Rac)-3′-Hydroxy simvastatin

Catalog No. :
ACUGVT438
CAS No. :
126313-98-2
Molecular Formula :
C25H38O6
Molecular Weight :
434.57

IUPAC Name:8-(2-(4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 3-hydroxy-2,2-dimethylbutanoate

(Rac)-3′-Hydroxy simvastatin structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(Rac)-3′-Hydroxy simvastatin
IUPAC Name8-(2-(4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 3-hydroxy-2,2-dimethylbutanoate
Molecular FormulaC25H38O6
Molecular Weight434.57
SMILESCC(C(C)(C(OC1CC(C=C2C=CC(C(C12)CCC3CC(CC(O3)=O)O)C)C)=O)C)O
InChI KeyMTOKLGKFIIZWRP-UHFFFAOYSA-N
Synonym(1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 3-hydroxy-2,2-dimethylbutanoate;3-Hydroxy-2,2-diMethylbutanoic Acid;Simvastatin beta-Hydroxy Impurity;Butanoic acid, 3-hydroxy-2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl ester;Simvastatin Impurity 8(EP-G);(Rac)-3′-Hydroxy simvastatin;Simvastatin beta-Hydroxy Impurity / 3-Hydroxy Simvastatin
CAS No.126313-98-2

Synthetic Route by SureRoute

1. ACUGVT438 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACNKFJ196 route compound structure diagram
    ACNKFJ19629269-83-8 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACUGVT438 route product structure diagram
    ACUGVT438126313-98-2
Inquiry

2. ACUGVT438 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACUGVT438 route product structure diagram
    ACUGVT438126313-98-2
Inquiry

Comments (0)